Corey Lacher

Corey Lacher

Auto-generated profile, based on publicly available information

Corey Lacher

Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, NJ, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in Journal of Ophthalmic and Vision Research
Verified
Journal Article
Open access
PDF file
CLCorey Lacher
Corey Lacher
ARAliya C. Roginiel
Aliya C. Roginiel
EBElmira Baghdasaryan
Elmira Baghdasaryan
ASAlexader A. Svoronos
Alexader A. Svoronos
PFPhilip J. Ferrone
Philip J. Ferrone
ICIsha Cheela
Isha Cheela
Purpose: To report the second documented case of spontaneous sickle cell retinopathy due to hemoglobin SE disease, and the third in association with this condition overall. Case Report: An asymptomatic 19-year-old African American woman with hemoglobin SE disease and no other significant past medical history presented for a routine eye exam. Fundoscopy revealed two sunburst lesions in the temporal periphery of her right eye and one such lesion in the temporal periphery of her left eye. No definitive signs of neovascularization were detected on fluorescein angiography, although multiple areas of abnormal vasculature and distal nonperfusion were observed. Conclusion: Spontaneous peripheral retinopathy can develop at an early age in hemoglobin SE disease. Given the risk for complications, pediatric screening with regular fundoscopic examination may benefit such patients.

1 October 2021 in Crohn's & Colitis 360
Verified
Journal Article
Open access
PDF file
JSJonathan M Schachne
Jonathan M Schachne
LDLaura L Durbin
Laura L Durbin
CLCorey R Lacher
Corey R Lacher
MSMaheep Sangha
Maheep Sangha
AMAnjali Mone
Anjali Mone
ASArun Swaminath
Arun Swaminath
Background: Infliximab is a weight-based prescription for multiple autoimmune diseases and is dispensed only in single-use, 100mg vials. We aim to compute the quantity of infliximab waste at our site and in an ideal world where weight-based prescribing practices are followed. We estimate hypothetical waste reduction and cost-savings if a smaller vial is dispensed. We also surveyed gastroenterologists to study prescription rounding practices for infliximab. Methods: A pre-existing registry of 426 inflammatory bowel disease patients identified 112 individuals who had received a total of 1003 infliximab administrations from December 2013 to May 2019. We calculated infliximab wastage per administration for the real world and an ideal (weight-based) world. Analysis of potential waste reduction and cost-savings was computed with the hypothetical creation of 50 and 25mg vials. Infliximab-prescribing gastroenterologists completed an online survey, determining reasons for rounding of weight-based prescription, rounding practices, and biosimilar use. Results: At our site, the total value of infliximab wasted was between $112738.08 and $243209.50. Utilizing 50 and 25mg vials would reduce this waste by 92.2% and 99.4%, respectively. If prescriber guidelines were followed precisely, the total value of waste was between $132781.08 and $286448.19. Utilizing 50 and 25mg vials would reduce waste by 50.39% and 75.34%, respectively. The physician survey revealed that 68.1% rounded doses while only 31.9% prescribed exact weight-based doses. Conclusions: Infliximab-prescribing gastroenterologists considered reducing drug waste as a common reason in their rounding practices. Our analysis demonstrates significant waste reduction and cost-savings are possible with the introduction of 50 and 25mg vials.